Merck stock has become dependent on its diabetes drug Januvia over the past couple of years for revenue growth. The franchise made up 12% of Merck's sales in the first quarter and probably a larger ...
CHICAGO, June 23 (Reuters) - Merck & Co.'s new diabetes pill, Januvia, improved blood sugar control when added to current therapies, according to data released on Saturday at a major medical meeting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback